Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07400653 · ClinicalTrials.gov registry record · Phase 3
A Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D)
A Phase 3 study, sponsored by Pfizer.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 999
- Enrollment target
NCT07400653 is a Phase 3 study that is actively recruiting participants, run by Pfizer. The registered enrollment target is 999 participants.
The verdict
NCT07400653, a Phase 3 study, is actively recruiting participants, sponsored by Pfizer.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 999 participants
- Enrollment target
Study Summary
The purpose of this clinical study is to learn about the safety and effects of the study medicine to help adults with obesity or overweight and type 2 diabetes lose weight. Being overweight or obese means carrying too much body weight. Type 2 diabetes is a condition where there is too much sugar in the blood. The study medicine is given by a shot under the skin in the belly area. The participants will be trained to do this at home once every week. About 660 out of 1000 adults will also receive the study medicine and about 330 out of 1000 adults will receive placebo. A placebo does not have any medicine in it but looks just like the medicine being studied. The investigators will compare the experiences of people receiving the study medicine to those of the people who do not. This will help us assess if the study medicine is safe and effective. People will take part in this study for about 21 months. During this time, they will have about 14 study visits at the site and 5 over the phone.
Interventions
- OTHER Placebo
- DRUG PF-08653944
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 999 participants |
| Start Date | 2026-02-24 |
| Est. Completion | 2028-05-16 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07400653
The ClinicalTrials.gov registry entry for NCT07400653 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 999 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07400653 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07400653 about?
NCT07400653 is a clinical study titled "A Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D)". The purpose of this clinical study is to learn about the safety and effects of the study medicine to help adults with obesity or overweight and type 2 diabetes lose weight. Being overweight or obese means carrying too much body weight. Type 2 diabetes is a condition where there is too much sugar in ...
What is the current status of trial NCT07400653?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 999 participants. The study started on 2026-02-24. Estimated completion is 2028-05-16.
What interventions are being tested in trial NCT07400653?
The interventions under investigation include: Placebo (OTHER), PF-08653944 (DRUG).
Who is sponsoring clinical trial NCT07400653?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.